Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SNV1521 · 1 trial · 2 indications
Number, type, and severity of treatment-emergent adverse events, serious adverse events, and dose-limiting toxicities in participants receiving SNV1521 plus daraxonrasib, used to identify doses suitable for further study, classified and graded according to CTCAE v6.0 and protocol-defined DLT criteria
| Arm | Type | Description |
|---|---|---|
| Escalation | EXPERIMENTAL | Participants in this arm will take SNV1521 by mouth together with a RAS-targeted cancer medicine. The dose of SNV1521 will be increased in small steps to find a safe and tolerable dose of the combination in people with advanced pancreatic cancer. |
| Name | Type | Description |
|---|---|---|
| SNV1521 | DRUG | SNV1521 is an oral investigational anticancer drug. In this study, SNV1521 is administered at different dose levels together with the RAS inhibitor daraxonrasib in adults with locally advanced unresectable or metastatic pancreatic cancer. |
| daraxonrasib | DRUG | Daraxonrasib is an oral targeted cancer medicine used in this study together with SNV1521. It is given once daily to help evaluate the safety and tolerability of the drug combination in people with advanced pancreatic cancer. |
Inclusion Criteria: * Adults (18 years and older). * Diagnosis of pancreatic cancer that cannot be removed by surgery or has spread to other parts of the body. * Cancer confirmed by tissue or cell examination (histology or cytology). * At least one measurable tumor on scans. * Good enough general h...
Top 20 of 68 competitors
SNV1521 is an investigational small molecule being studied for the treatment of advanced pancreatic cancer, including pancreatic acinar carcinoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SNV1521 is being developed by Revolution Medicines, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol RVMD.
SNV1521 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by the FDA or other regulatory agencies and is still being evaluated in clinical trials.
SNV1521 is being studied in a Phase 1 first-in-human trial with the identifier NCT07756281. The trial is titled 'First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer' and is not yet recruiting participants.
SNV1521 is a small molecule being studied in combination with a RAS inhibitor for the treatment of advanced pancreatic cancer. The specific molecular target of SNV1521 has not been disclosed in available information.